Literature DB >> 22068526

Hepatitis C: move over interferon.

Ken Garber.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22068526     DOI： 10.1038/nbt.2031

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN： 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  7 in total

1.  Discovery and development of telaprevir: an NS3-4A protease inhibitor for treating genotype 1 chronic hepatitis C virus.

Authors:  Ann D Kwong; Robert S Kauffman; Patricia Hurter; Peter Mueller
Journal:  Nat Biotechnol       Date:  2011-11-08       Impact factor: 54.908

2.  Hepatitis C: staying the course.

Authors:  Ken Garber
Journal:  Nat Biotechnol       Date:  2007-12       Impact factor: 54.908

3.  Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance.

Authors:  Dongliang Ge; Jacques Fellay; Alexander J Thompson; Jason S Simon; Kevin V Shianna; Thomas J Urban; Erin L Heinzen; Ping Qiu; Arthur H Bertelsen; Andrew J Muir; Mark Sulkowski; John G McHutchison; David B Goldstein
Journal:  Nature       Date:  2009-08-16       Impact factor: 49.962

4.  Structure of the zinc-binding domain of an essential component of the hepatitis C virus replicase.

Authors:  Timothy L Tellinghuisen; Joseph Marcotrigiano; Charles M Rice
Journal:  Nature       Date:  2005-05-19       Impact factor: 49.962

5.  Hepatitis C: An unsuspected drug target.

Authors:  Catherine L Murray; Charles M Rice
Journal:  Nature       Date:  2010-05-06       Impact factor: 49.962

6.  Genetic variation in IL28B and spontaneous clearance of hepatitis C virus.

Authors:  David L Thomas; Chloe L Thio; Maureen P Martin; Ying Qi; Dongliang Ge; Colm O'Huigin; Judith Kidd; Kenneth Kidd; Salim I Khakoo; Graeme Alexander; James J Goedert; Gregory D Kirk; Sharyne M Donfield; Hugo R Rosen; Leslie H Tobler; Michael P Busch; John G McHutchison; David B Goldstein; Mary Carrington
Journal:  Nature       Date:  2009-10-08       Impact factor: 49.962

7.  Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect.

Authors:  Min Gao; Richard E Nettles; Makonen Belema; Lawrence B Snyder; Van N Nguyen; Robert A Fridell; Michael H Serrano-Wu; David R Langley; Jin-Hua Sun; Donald R O'Boyle; Julie A Lemm; Chunfu Wang; Jay O Knipe; Caly Chien; Richard J Colonno; Dennis M Grasela; Nicholas A Meanwell; Lawrence G Hamann
Journal:  Nature       Date:  2010-04-21       Impact factor: 49.962
  7 in total
  9 in total

1.  Inhibition of hepatitis C virus NS5B polymerase by S-trityl-L-cysteine derivatives.

Authors:  Daniel B Nichols; Guy Fournet; K R Gurukumar; Amartya Basu; Jin-Ching Lee; Naoya Sakamoto; Frank Kozielski; Ira Musmuca; Benoît Joseph; Rino Ragno; Neerja Kaushik-Basu
Journal:  Eur J Med Chem       Date:  2012-01-12       Impact factor: 6.514

2.  FDA approvals usher in the post-interferon era in HCV.

Authors:  Cormac Sheridan
Journal:  Nat Biotechnol       Date:  2014-01       Impact factor: 54.908

3.  Fluorescent primuline derivatives inhibit hepatitis C virus NS3-catalyzed RNA unwinding, peptide hydrolysis and viral replicase formation.

Authors:  Jean Ndjomou; Rajesh Kolli; Sourav Mukherjee; William R Shadrick; Alicia M Hanson; Noreena L Sweeney; Diana Bartczak; Kelin Li; Kevin J Frankowski; Frank J Schoenen; David N Frick
Journal:  Antiviral Res       Date:  2012-08-25       Impact factor: 5.970

4.  Sulfur(vi) fluoride exchange as a key reaction for synthesizing biaryl sulfate core derivatives as potent hepatitis C virus NS5A inhibitors and their structure-activity relationship studies.

Authors:  Youngsu You; Hee Sun Kim; Jung Woo Park; Gyochang Keum; Sung Key Jang; B Moon Kim
Journal:  RSC Adv       Date:  2018-09-12       Impact factor: 4.036

5.  2-Heteroarylimino-5-arylidene-4-thiazolidinones as a new class of non-nucleoside inhibitors of HCV NS5B polymerase.

Authors:  Ilkay Küçükgüzel; Gökhan Satılmış; K R Gurukumar; Amartya Basu; Esra Tatar; Daniel B Nichols; Tanaji T Talele; Neerja Kaushik-Basu
Journal:  Eur J Med Chem       Date:  2013-09-12       Impact factor: 6.514

6.  Viral genome imaging of hepatitis C virus to probe heterogeneous viral infection and responses to antiviral therapies.

Authors:  Vyas Ramanan; Kartik Trehan; Mei-Lyn Ong; Joseph M Luna; Hans-Heinrich Hoffmann; Christine Espiritu; Timothy P Sheahan; Hamsika Chandrasekar; Robert E Schwartz; Kathleen S Christine; Charles M Rice; Alexander van Oudenaarden; Sangeeta N Bhatia
Journal:  Virology       Date:  2016-04-27       Impact factor: 3.616

7.  Design and synthesis of L- and D-phenylalanine derived rhodanines with novel C5-arylidenes as inhibitors of HCV NS5B polymerase.

Authors:  Bhargav A Patel; Ramalingam Krishnan; Nikhil Khadtare; K R Gurukumar; Amartya Basu; Payal Arora; Aaditya Bhatt; Maulik R Patel; Dibyendu Dana; Sanjai Kumar; Neerja Kaushik-Basu; Tanaji T Talele
Journal:  Bioorg Med Chem       Date:  2013-03-31       Impact factor: 3.641

8.  Discovery of new scaffolds for rational design of HCV NS5B polymerase inhibitors.

Authors:  Andriy G Golub; K R Gurukumar; Amartya Basu; Volodymyr G Bdzhola; Yaroslav Bilokin; Sergiy M Yarmoluk; Jin-Ching Lee; Tanaji T Talele; Daniel B Nichols; Neerja Kaushik-Basu
Journal:  Eur J Med Chem       Date:  2012-09-17       Impact factor: 6.514

Review 9.  Discovering new medicines targeting helicases: challenges and recent progress.

Authors:  William R Shadrick; Jean Ndjomou; Rajesh Kolli; Sourav Mukherjee; Alicia M Hanson; David N Frick
Journal:  J Biomol Screen       Date:  2013-03-27
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.